Disturbed skin microbiome increases the risk of radiodermatitis in radiotherapy patients, finds study medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Dr Abdou discusses how characteristics of patients with breast cancer impact ADC treatment selection and highlights some of the topline takeaways from breast cancer treatment to come out of the 2023 ASCO Annual Meeting.
HER2-targeted therapies improve outcomes by shutting down growth signaling to cancer cells, targeted delivery of chemotherapy, or blocking intracellular signaling - all leveraging the HER2 receptor to better control metastatic breast cancer.
Sara M. Tolaney, MD, MPH explains that treatment decisions for metastatic breast cancer are based on the current biopsy showing receptor status, but prior biopsies over the full course of disease are considered as well, particularly for HER2 targeted therapies which may work even if HER2 low expression occurred years earlier.
Treatment for HER2-negative metastatic breast cancer depends on factors like hormone receptor status, with chemo/immunotherapy for PD-L1-positive triple negative disease, PARP inhibitors for BRCA mutations, and antibody-drug conjugates as options after first line therapy.